Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Amarin Corporation plc (NASDAQ:AMRN) has announced that its CEO, Karim Mikhail, and CFO, Michael Kalb, will participate in two upcoming investor conferences. The Jefferies 2021 London Healthcare Conference is scheduled for November 16, 2021, at 1:40 pm GMT, featuring a corporate presentation by Mikhail. Additionally, the Piper Sandler 33rd Annual Virtual Healthcare Conference will be available on-demand starting November 22, 2021, with Mikhail participating in a fireside chat. Live audio webcasts can be accessed through the company’s investor relations website.
Amarin Corporation plc (NASDAQ: AMRN) announced the presentation of new VASCEPA®/VAZKEPA (icosapent ethyl) data at the AHA Scientific Sessions 2021 from November 13-15. Key findings highlight the drug's benefits for patients at risk of major cardiovascular events. The company will host a virtual exhibit booth, with additional programs including a Product Theater and Continuing Medical Education session, to enhance awareness of cardiovascular risk reduction. CEO Karim Mikhail emphasized the importance of engaging healthcare providers through digital strategies.
Amarin Corporation (NASDAQ: AMRN) reported Q3 2021 net revenue of $142.0 million, down 9% from Q3 2020, and $438.7 million for the nine months ending September 30, 2021, a 2% decline. The launch of VAZKEPA in Germany and regulatory submissions for reimbursement in ten European countries were significant highlights. Despite the competitive landscape with generics, Amarin retains approximately 83% of the U.S. icosapent ethyl market. The company ended Q3 with $517.9 million in cash. Ongoing efforts on market access and digital strategies aim to enhance VASCEPA demand.
BYOMass has appointed Dr. Declan Doogan and Dr. Stephen Hoffman to its Board of Directors. Dr. Doogan, a pharmaceutical veteran, previously led drug development at Pfizer and was Head of R&D at Amarin Corporation. Dr. Hoffman brings extensive experience from Aerpio Pharmaceuticals and has served on multiple biotech boards. Their expertise is expected to guide BYOMass’s innovative pipeline targeting the TGF-β superfamily, potentially improving therapies for diseases with high unmet medical needs.
Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on November 3, 2021, at 7:30 a.m. ET to discuss its third quarter 2021 financial results. The call follows the anticipated release of financial results earlier that day. It can be accessed live via Amarin’s website or through designated phone numbers. A replay will be available for two weeks post-call. Amarin focuses on cardiovascular disease management and aims to enhance the treatment of cardiovascular risk.
Amarin Corporation plc (NASDAQ: AMRN) has announced a new Go-to-Market strategy to enhance the growth of VASCEPA® (icosapent ethyl) in the U.S. This includes improving healthcare professional engagement through an omnichannel platform, enhancing managed care access, and optimizing prescriptions for cardiovascular risk reduction. The strategy will reduce the U.S. sales force to approximately 300 representatives, reallocating resources towards educational efforts. Amarin aims to drive VASCEPA growth amidst increasing demand for cardiovascular therapies, emphasizing the drug's unique position as the only FDA-approved IPE product for CV risk reduction.
Amarin Corporation has successfully launched VAZKEPA (icosapent ethyl) in Germany, marking its first entry into the European market. VAZKEPA is designed to reduce cardiovascular risks in statin-treated adults with elevated triglycerides. The drug received approval from the European Commission in March 2021. Backed by over a decade of research, including the REDUCE-IT® study, VAZKEPA is endorsed by key cardiovascular disease treatment guidelines. The launch is a part of Amarin's growth strategy, aiming to address the significant cardiovascular burden in Europe, where CVD is the leading cause of death.
Amarin Corporation plc (NASDAQ: AMRN) announced participation in two upcoming virtual investment conferences in September 2021. The H. C. Wainwright 23rd Annual Global Investment Conference will feature an on-demand presentation available on September 13, 2021, at 7:00 a.m. ET. The Cantor Fitzgerald Global Healthcare Conference 2021 will include a live presentation on September 28, 2021, at 2:40 p.m. ET. Both presentations will be webcast live and archived for 90 days on Amarin's Investor Relations website.
Amarin Corporation (NASDAQ:AMRN) announced significant findings related to VASCEPA/VAZKEPA presented at ESC Congress 2021. The data revealed a 26% reduction in first and 35% reduction in total primary endpoints for patients with a history of myocardial infarction, reinforcing VASCEPA's role in cardiovascular risk reduction. Additionally, VAZKEPA was included in the 2021 ESC Guidelines for patients with elevated triglycerides, marking its 20th recognition in global guidelines. Despite promising findings, the identical PREPARE-IT 1 trial did not meet its primary endpoint.
Amarin Corporation (NASDAQ:AMRN) presented new analyses of VASCEPA® (icosapent ethyl) at ESC Congress 2021, revealing it reduces major adverse cardiovascular events in patients with prior myocardial infarction (MI) by 26% and total primary endpoints by 35%. Conducted as part of the REDUCE-IT study, these findings highlight VASCEPA's importance in cardiovascular risk management. Experts emphasize its efficacy in patients at high risk for recurrent events, further supporting its role as a treatment beyond statins.